ATAZANAVIR SULFATE | N021567 | BRISTOL MYERS SQUIBB CO
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2017-10-24 | Terminated 2018-02-14 | — | |
Bristol-Myers Squibb Company v. Cipla USA, Inc. et al 1 patentANDA 200626atazanavir sulfate | D. Del. | 2016-02-11 | Terminated 2016-08-05 | — |
Bristol-Myers Squibb Company et al v. Teva Pharmaceuticals USA Inc. 2 patentsANDA 91673atazanavir bisulfate | D. Del. | 2010-04-01 | Terminated 2011-10-24 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition From Lachman Consultant Services Inc FDA-2014-P-0980 · 4 docket documents Lachman Consultant Services, Inc. filed this petition on behalf of a client requesting that the FDA determine whether REYATAZ (atazanavir sulfate) Capsules, 100 mg, approved under NDA 21-567, was voluntarily withdrawn from the market for safety or efficacy reasons rather than commercial reasons, in | 505(q) | 2014-07-11 | Denied | Lachman Consultant Services Inc |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.